BIEL could offer Electrome several strategic advantages that might justify a minority stake—such as 5%—especially if Electrome is looking to expand its footprint in bioelectronic therapeutics. Here's how BIEL could benefit Electrome:

Strategic Benefits Electrome Could Gain from BIEL
1. Established Product Portfolio
BIEL already has FDA-cleared products like ActiPatch and RecoveryRx with proven market traction.

Electrome could leverage BIEL’s distribution channels and customer base to accelerate adoption of its own devices.

2. Regulatory Experience
BIEL has navigated the FDA 510(k) process multiple times. Electrome could benefit from BIEL’s regulatory expertise, especially if they plan to expand indications or enter new therapeutic categories.

3. Manufacturing & Supply Chain Infrastructure
BIEL’s existing manufacturing capabilities could help Electrome scale production faster and more cost-effectively than building from scratch.

4. Brand Recognition & Market Access
BIEL has brand equity in pain management and recovery markets. Electrome could piggyback on this to gain credibility and access in overlapping segments.

5. R&D Collaboration
Electrome’s AI-powered discovery engine could be paired with BIEL’s clinical data and device history to identify new bioelectric targets or optimize protocols.

6. Financial Upside
If BIEL’s stock is undervalued or poised for growth, a 5% stake could be a smart financial play for Electrome—especially if tied to a strategic partnership or joint venture.

Could Electrome Buy a 5% Stake?
It’s plausible. A 5% stake is modest enough to avoid control issues but meaningful enough to signal strategic alignment. Electrome is actively raising capital and seeking partnerships, so acquiring a minority stake in BIEL could:

Strengthen its supply chain.

Accelerate market entry.

Create a foundation for deeper collaboration.

If BIEL is open to equity-based partnerships, this could be a win-win.